J&J Has 18.2% OTC Drug Sales Increase In Hand, But Not Decision On Talc Business Bankruptcy Plan

J&J reported worldwide consumer health and personal care product Q3 sales up 4.1% to $3.7bn driven by 18.2% increase in OTC drug sales. Excluding OTC, its consumer business results would have been down as sales for all other sectors slipped.

• Source: Alamy

Johnson & Johnson’s outlook in the consumer health and personal care products space is bifurcated by what’s under its control or out of its hands, management explained with the firm’s latest quarterly results.

Manufacturing and marketing the products is in J&J’s hands.

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Earnings

More from Business